The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101
Open accessAbstract
IMPORTANCE: Although consensus statements support the preoperative treatment of borderline resectable pancreatic cancer, no prospective, quality-controlled, multicenter studies of this strategy have been conducted. Existing studies are retrospective and confounded by heterogeneity in patients studied, therapeutic algorithms used, and outcomes reported. OBJECTIVE: To determine the feasibility of conducting studies of multimodality therapy for borderline resectable pancreatic cancer in the cooperative group setting. DESIGN, SETTING, AND PARTICIPANTS: A prospective, multicenter, single-arm trial of a multimodality treatment regimen administered within a study framework using centralized quality control with the cooperation of 14 member institutions of the National Clinical Trials Network. Twenty-nine patients with biopsy-confirmed pancreatic cancer preregistered, and 23 patients with tumors who met centrally reviewed radiographic criteria registered. Twenty-two patients initiated therapy (median age, 64 years [range, 50-76 years]; 55% female). Patients registered between May 29, 2013, and February 7, 2014. INTERVENTIONS: Patients received modified FOLFIRINOX treatment (85 mg/m2 of oxaliplatin, 180 mg/m2 of irinotecan hydrochloride, 400 mg/m2 of leucovorin calcium, and then 2400 mg/m2 of 5-fluorouracil for 4 cycles) followed by 5.5 weeks of external-beam radiation (50.4 Gy delivered in 28 daily fractions) with capecitabine (825 mg/m2 orally twice daily) prior to pancreatectomy. MAIN OUTCOMES AND MEASURES: Feasibility, defined by the accrual rate, the safety of the preoperative regimen, and the pancreatectomy rate. RESULTS: The accrual rate of 2.6 patients per month was superior to the anticipated rate. Although 14 of the 22 patients (64% [95% CI, 41%-83%]) had grade 3 or higher adverse events, 15 of the 22 patients (68% [95% CI, 49%-88%]) underwent pancreatectomy. Of these 15 patients, 12 (80%) required vascular resection, 14 (93%) had microscopically negative margins, 5 (33%) had specimens that had less than 5% residual cancer cells, and 2 (13%) had specimens that had pathologic complete responses. The median overall survival of all patients was 21.7 months (95% CI, 15.7 to not reached) from registration. CONCLUSIONS AND RELEVANCE: The successful completion of this collaborative study demonstrates the feasibility of conducting quality-controlled trials for this disease stage in the multi-institutional setting. The data generated by this study and the logistical elements that facilitated the trial's completion are currently being used to develop cooperative group trials with the goal of improving outcomes for this subset of patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01821612.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Self-citation(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Practical Statistics for Medical Research.
Walter, S. D., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,668
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Practical Statistics for Medical Research.
Bartko, J. J., & Altman, D. G. (1992) · Journal of the American Statistical Association · doi:10.2307/2290246 · Cited by 4,797
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Gillen, S., Schuster, T., Meyer zum Büschenfelde, C., Friess, H., & Kleeff, J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000267 · Cited by 1,552
Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M. J., Gallinger, S., Mariette, C., et al. (2010) · JAMA · doi:10.1001/jama.2010.1275 · Cited by 1,397
10.1016/b978-0-323-67762-2.50051-3
(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/b978-0-323-67762-2.50051-3 · Cited by 1,156
Callery, M. P., Chang, K. J., Fishman, E. K., Talamonti, M. S., William Traverso, L., & Linehan, D. C. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0408-6 · Cited by 902
Self-citationBorderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
Varadhachary, G. R., Tamm, E. P., Abbruzzese, J. L., Xiong, H. Q., Crane, C. H., Wang, H., Lee, J. E., Pisters, P. W. T., Evans, D. B., & Wolff, R. A. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.08.011 · Cited by 876
Ferrone, C. R., Marchegiani, G., Hong, T. S., Ryan, D. P., Deshpande, V., McDonnell, E. I., Sabbatino, F., Santos, D. D., Allen, J. N., Blaszkowsky, L. S., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000867 · Cited by 842
Katz, M. H. G., Fleming, J. B., Bhosale, P., Varadhachary, G., Lee, J. E., Wolff, R., Wang, H., Abbruzzese, J., Pisters, P. W. T., Vauthey, J., et al. (2012) · Cancer · doi:10.1002/cncr.27636 · Cited by 536
Self-citationKatz, M. H. G., Marsh, R., Herman, J. M., Shi, Q., Collison, E., Venook, A. P., Kindler, H. L., Alberts, S. R., Philip, P., Lowy, A. M., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2886-9 · Cited by 340
Self-citationAbrams, R. A., Lowy, A. M., O’Reilly, E. M., Wolff, R. A., Picozzi, V. J., & Pisters, P. W. T. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0413-9 · Cited by 286
Self-citationChatterjee, D., Katz, M. H., Rashid, A., Varadhachary, G. R., Wolff, R. A., Wang, H., Lee, J. E., Pisters, P. W. T., Vauthey, J., Crane, C., et al. (2012) · Cancer · doi:10.1002/cncr.26651 · Cited by 260
Self-citationMahaseth, H., Brutcher, E., Kauh, J., Hawk, N., Kim, S., Chen, Z., Kooby, D. A., Maithel, S. K., Landry, J., & El-Rayes, B. F. (2013) · Pancreas · doi:10.1097/mpa.0b013e31829e2006 · Cited by 208
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer
Boone, B. A., Steve, J., Krasinskas, A. M., Zureikat, A. H., Lembersky, B. C., Gibson, M. K., Stoller, R. G., Zeh, H. J., & Bahary, N. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23392 · Cited by 193
Nakao, A., Kanzaki, A., Fujii, T., Kodera, Y., Yamada, S., Sugimoto, H., Nomoto, S., Nakamura, S., Morita, S., & Takeda, S. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318237872e · Cited by 190
Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?
Christians, K. K., Tsai, S., Mahmoud, A., Ritch, P., Thomas, J. P., Wiebe, L., Kelly, T., Erickson, B., Wang, H., Evans, D. B., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0273 · Cited by 190
FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma
Sadot, E., Doussot, A., O’Reilly, E. M., Lowery, M. A., Goodman, K. A., Do, R. K. G., Tang, L. H., Gönen, M., D’Angelica, M. I., DeMatteo, R. P., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4647-4 · Cited by 161
Landry, J. C., Catalano, P. J., Staley, C. A., Harris, W. B., Hoffman, J., Talamonti, M., Xu, N., Cooper, H. S., & Benson, A. B. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21527 · Cited by 151
Self-citationAggressive Surgery for Borderline Resectable Pancreatic Cancer
Yamada, S., Fujii, T., Sugimoto, H., Nomoto, S., Takeda, S., Kodera, Y., & Nakao, A. (2013) · Pancreas · doi:10.1097/mpa.0b013e31827b2d7c · Cited by 96
Katz, M. H. G., Merchant, N. B., Brower, S. T., Branda, M. E., Posner, M. C., Traverso, L. W., Abrams, R. A., Picozzi, V. J., & Pisters, P. W. T. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1282-y · Cited by 78
Self-citationAmerican Joint Committee on Cancer
National Cancer Institute (2020) · Definitions · doi:10.32388/9f0l2o · Cited by 69
Cited by
Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30974-0 · Cited by 2,559
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Isaji, S., Mizuno, S., Windsor, J. A., Bassi, C., Fernández-del Castillo, C., Hackert, T., Hayasaki, A., Katz, M. H. G., Kim, S.-W., Kishiwada, M., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2017.11.011 · Cited by 797
Self-citationJang, J.-Y., Han, Y., Lee, H., Kim, S.-W., Kwon, W., Lee, K.-H., Oh, D.-Y., Chie, E. K., Lee, J. M., Heo, J. S., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002705 · Cited by 681
Murphy, J. E., Wo, J. Y., Ryan, D. P., Jiang, W., Yeap, B. Y., Drapek, L. C., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Clark, J. W., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0329 · Cited by 531
Metadata
- Authors
- Katz, M. H. G., Shi, Q., Ahmad, S. A., Herman, J. M., Marsh, R. D. W., Collisson, E., Schwartz, L., Frankel, W., Martin, R., Conway, W., Truty, M., Kindler, H., Lowy, A. M., Bekaii-Saab, T., Philip, P., Talamonti, M., Cardin, D., LoConte, N., Shen, P., Hoffman, J. P., & Venook, A. P.
- Venue
- JAMA Surgery
- Publisher
- American Medical Association (AMA)
- Published
- 2016-08-17
- Volume
- 151
- Issue
- 8
- Pages
- e161137
- ISSN
- 2168-6254 (ISSN-L)
- OpenAlex
- W2409856225
- Cited by
- 448
- References
- 28
- FWCI
- 22.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.